tbuckley/cabot-search huggingface dataset:
Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience
Authors: Pervin Topcuoglu, Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Klara Dalva, Onder Arslan, Muhit Özcan, Taner Demirer, Osman Ilhan, Meral Beksac, Gunhan Gurman
Journal: Blood (2018)
Early CMV Replication-Associated Anti-Leukemia Effect Is Related to the Reconstitution of Specific Subsets of Natural Killer Cells after Haploidentical Stem Cell Transplantation in Acute Leukemia
Authors: Jieun Jang, Haerim Chung, Yu Ri Kim, Hoi-kyung Jeung, Ju-In Eom, So-Young Seol, Soo-Jeong Kim, Jin Seok Kim, June-Won Cheong, Yoo Hong Min
Journal: Blood (2018)
Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016
Authors: Peter A. Kahn, Sanket S. Dhruva, Taeho Greg Rhee, Joseph S. Ross
Journal: JAMA Network Open (2019)

Out-of-hospital cardiac arrest is a common scenario facing prehospital emergency medical services (EMS) professionals and nearly always involves either manual or mechanical cardiopulmonary resuscitation (CPR). Mechanical CPR devices are expensive and prior clinical trials have not provided evidence of benefit for patients when compared with manual CPR.To investigate the use of mechanical CPR in the prehospital setting and determine whether patient demographic characteristics or geographical location is associated with its use.A retrospective cross-sectional study was performed using the 2010 through 2016 National Emergency Medical Services Information System data. Participants included all patients identified by EMS professionals as having out-of-hospital cardiac arrest.Use of CPR, categorized as manual or mechanical.From 2010 to 2016, 892 022 patients (38.6% female, 60.4% male, missing for 1%; mean [SD] age, 61.1 [20.5] years) with out-of-hospital cardiac arrest were identified by EMS professionals. Overall, manual CPR was used for 618 171 patients (69.3%) and mechanical CPR was used for 45 493 patients (5.1%). The risk-standardized rate of mechanical CPR use, accounting for patient demographic and geographical characteristics, rose from 1.9% in 2010 to 8.0% in 2016 (P < .001). In multivariable analyses, use of mechanical CPR devices was increasingly likely over time among patients identified with out-of-hospital cardiac arrest treated by EMS professionals, increasing from an adjusted odds ratio of 1.58 (95% CI, 1.42-1.77; P < .001) when comparing 2011 with 2010, to an adjusted odds ratio of 11.32 (95% CI, 10.22-12.54; P < .001) when comparing 2016 with 2010. In addition, several other patient demographic and geographical characteristics were associated with a higher likelihood of receiving mechanical CPR, including being 65 years or older, being male, being Hispanic, as well as receiving treatment in the Northeast Census Region, in a suburban location, or in a zip code with a median annual income greater than $20 000.Mechanical CPR device use increased more than 4-fold among patients with out-of-hospital cardiac arrest treated by EMS professionals. Given the high costs of mechanical CPR devices, better evidence is needed to determine whether these devices improve clinically meaningful outcomes for patients treated for out-of-hospital cardiac arrest by prehospital EMS professionals to justify the significant increase in their use.
Inhibitory Spleen-Derived Anti-ADAMTS13 Antibodies Are Characterized by a Limited Number of Variable Heavy Chain CDR3 Signatures in Patients with Relapsing Acquired Thrombotic Thromobocytopenic Purpura
Authors: Monica Schaller, Gianna Tanno, Irmela Sulzer, Monique Vogel, Karim Kentouche, Bernhard Laemmle, Johanna A. Kremer Hovinga Strebel
Journal: Blood (2011)
Abstract 825: Attenuation of Cardiac Fibrosis by Scleraxis Gene Deletion Improves Pressure Overload-Induced Cardiac Remodeling
Authors: Raghu S Nagalingam, David Y Cheung, Nina Aroutiounova, Davinder S Jassal, Michael P Czubryt
Journal: Circulation Research (2019)

Cardiac fibrosis is a significant independent risk factor for heart failure with increasing incidence. The fibrotic myocardium shows increased arrhythmogenesis, and poor pumping and relaxation due to greater tissue stiffness. A critical step in this process is the conversion of fibroblasts to myofibroblasts, which are responsible for excessive extracellular matrix (ECM) production; limiting this conversion may reduce fibrosis and restore cardiac function. We previously reported that the transcription factor scleraxis, following mechanical stretch or TGFβ signaling, is both sufficient and necessary to convert fibroblasts to myofibroblasts by direct transcriptional control of myofibroblast genes including collagens, α-smooth muscle actin and fibronectin. In a pressure overload transverse aorta constriction (TAC) mouse model analyzed by echocardiography, we found that fibroblast-specific scleraxis gene deletion prior to TAC using a tamoxifen-inducible TCF21-Cre/loxP approach attenuated both systolic (LV ejection fraction, fractional shortening) and diastolic (early and late filling velocity) dysfunction, as well as chamber dilation, despite persistent hypertrophy. Functional improvement was matched by an almost complete attenuation of cardiac fibrosis (Masson’s trichrome; qPCR and western blots for fibrillar collagens and ED-A fibronectin). Scleraxis deletion also prevented induction of the myofibroblast marker periostin, suggesting a failure of scleraxis-null fibroblasts to convert to myofibroblasts. We next tested if scleraxis deletion 4 weeks post-TAC could reverse subsequent remodeling at 8 weeks post-TAC. Adverse remodeling occurred in all animals 4 weeks post-TAC (prior to scleraxis deletion), but cardiac function and chamber dimensions subsequently declined further in scleraxis-intact animals, while scleraxis-deleted animals showed preserved or improved cardiac function and morphology. Our results demonstrate that scleraxis is required for the initiation and progression of cardiac fibrosis, and that reducing fibrosis alone improves cardiac performance and morphology even in the presence of persistent pressure overload. Scleraxis is thus an important target for anti-fibrotic therapy development.
Induced Myelosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups
Authors: Dirk Pleimes, Volker Möbus, Frank Mayer, Marcus Schmidt, Corinna Asang, Kathrin Flunkert, Gerd Mikus
Journal: Blood (2018)
Inflammatory Bowel Disease and Hodgkin's Lymphoma: Two New Observations
Authors: Zoubida Tazi Mezalek, Myriam Bourkia, Sofia Habib Allah, Noha Al Waragli, Majdouline Bouaouad, Amina Lhoussni, Hajar Khibri, Wafaa Ammouri, Mouna Maamar, Hicham Harmouche, Mohammed Adnaoui
Journal: Blood (2018)
Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
Authors: Andrew J. Cowan, Philip A. Stevenson, Noam Kopmar, Edward N. Libby, Pamela S. Becker, David G. Coffey, Sherilyn A. Tuazon, Damian J. Green, Ajay K. Gopal, Leona A. Holmberg
Journal: Blood (2018)
Successful creation of an outpatient team-based model for traditionally inpatient chemotherapy.
Authors: Timothy Edward Kubal, Christopher Salamanca, Katherine Tobon, Amber Lubas, Diedra K. Frantz, Rebecca Nelson, Melissa Smith, Karen Wartenberg, Jeffrey E. Lancet
Journal: Journal of Clinical Oncology (2019)

86 Background: In 2014, due to increased demand for inpatient hospital beds and subsequent patient dissatisfaction due to delays for patients receiving scheduled chemotherapy, Moffitt Cancer Center created a multi-disciplinary team to transition traditionally inpatient chemotherapy regimens into the outpatient setting. Methods: A Team composed of Physicians, Pharmacists, PA’s/ARNP’s, Social work, Infusion Nursing and IT drove initiation and implementation of new processes from 2014-Current with gradual increases in patient volumes and continued high quality and patient safety. Results: Over the examined 5 year time period, HyperCVAD Arm A, DA-EPOCH, Blinatumomab and Liposomal Daunorubicin and Cytarabine (Vyxeos) were transitioned into the outpatient setting. 667 total cycles of chemotherapy were transitioned into the outpatient setting, saving 4,386 inpatient days over the examined time period. Hospitalization was required in 22 of 667 cycles (3.3%) with no attributable mortality due to outpatient administration. Examination of potential financial impact was consistent with an estimated favorable impact to overall margin of $3,153,534 due to backfill of inpatient beds. Conclusions: Outpatient delivery of traditionally inpatient chemotherapy is safe and effective with the potential for reduction in delays for scheduled chemotherapy patients and favorable financial impact. Critical to success is the creation of an empowered, cross functional leadership team and a gradual and sequential approach to implementation.
P53 and CD34 Immunohistochemical Expression on Bone Marrow Biopsy As Predictive Marker of Response to Erythropoietin in Low Risk Myelodysplastic Syndrome
Authors: Gianluigi Reda, Francesca Boggio, Ramona Cassin, Marta Riva, Marco Barella, Alessandro del Gobbo, Laura Bandiera, Emanuela Bonoldi, Alfredo Molteni, Agostino Cortelezzi, Umberto Gianelli
Journal: Blood (2018)
A Longitudinal Study of Ebola Sequelae in Liberia
Authors: Michael C Sneller, Cavan Reilly, Moses Badio, Rachel J Bishop, Allen O Eghrari, Soka J Moses, Kumblytee L Johnson, Dehkontee Gayedyu-Dennis, Lisa E Hensley, Elizabeth S Higgs, Avindra Nath, Kaylie Tuznik, Justin Varughese, Kenneth S Jensen, Bonnie Dighero-Kemp, James D Neaton, H Clifford Lane, Mosoka P Fallah
Journal: New England Journal of Medicine (2019)

Multiple health problems have been reported in survivors of Ebola virus disease (EVD). Attribution of these problems to the disease without a control group for analysis is difficult.
Evaluating the early impact of adding a financial counselor to an Oncology Care Model pilot program.
Authors: Margaret Liang, Sarah S. Summerlin, Gabrielle Betty Rocque, Terri Salter, Mark Wiersma, Warner King Huh
Journal: Journal of Clinical Oncology (2019)

67 Background: The Oncology Care Model (OCM) emphasizes the importance of patient costs. Our practice identified a need for patient financial counseling (Plan) and added a financial counselor to the care team (Do). Our objective is to describe the financial counseling process and evaluate (Study) the impact of adding a financial counselor to address financial burden among cancer patients. Methods: New treatment orders trigger a task to the financial counselor who mails a letter including personalized insurance benefit information (i.e., deductible, out of pocket maximum, amount met to date), estimated out of pocket cost for prescribed chemotherapy regimen, and additional financial resources. The health care team can also place referrals for identified needs. Data on patient characteristics, referral patterns, and services delivered was abstracted from the electronic medical record. Results: The financial counselor contacted 157 cancer patients from 4/2018-4/2019, including 134 (85%) OCM patients. The average age was 68 years old (range 22-91); 93 (59%) patients were female; 39 (25%) patients identified as black. Out of 32 patients with documented income, the average annual household income was $25,000. Most patients had Medicare Part D coverage (67/73, 92%) and secondary insurance (59/77, 77%). The financial counselor contacted patients by mail (52/77, 68%), phone (13/77, 17%), in-person at clinic (7/77, 9%), e-mail (1/77, 1%), or using multiple methods (4/77, 5%). Actions taken included mailing insurance benefit and estimated out of pocket cost letters (60/72, 83%), referring to social workers or lay navigators (5/72, 7%), or reviewing insurance benefits (4/72, 6%). Co-pay applications through foundation grants were submitted by the financial counselor for 27 patients of which most (23/27, 85%) were approved. Conclusions: Financial counselors provide diverse services to cancer patients to reduce financial burden, including to patients without secondary insurance who were noted to have additional financial needs. Patient satisfaction surveys and accounting for the dollar amount returned to patients and the health system represent next steps for our new program (Act).
Arkaitz Carracedo: If the scientific question is good, the result will be interesting
Authors: Stephanie Houston
Journal: The Journal of Experimental Medicine (2019)

Arkaitz Carracedo is a principal investigator at the Association for Cooperative Research in Biosciences (CIC bioGUNE) in Spain; his laboratory focuses on signaling and metabolic alterations in cancer. Arkaitz has investigated the regulation of fatty acid oxidation in cancer cells and how these changes could be manipulated therapeutically. We chatted with Arkaitz to find out about his career in science so far.
Abstract 772: The Highly Prevalent 25bp Intronic Deletion in <i>MYBPC3</i> is Benign Under Baseline Conditions
Authors: James W McNamara, Jennifer A Schwanekamp, Parth N Patel, Shiv K Viswanathan, Mohammad Bohlooly, Katja Madeyski-Bengtson, Ralph Knöll, Jonathan G Seidman, Christine E Seidman, Sakthivel Sadayappan
Journal: Circulation Research (2019)

Background: Hypertrophic cardiomyopathy (HCM) affects at least 1 in 500 people worldwide, and results in the thickening of the ventricular walls and reduced cardiac function. Mutations in MYBPC3 , encoding cardiac myosin binding protein-C, are the most common cause of HCM. Previously, a highly prevalent 25bp deletion within intron 32 of MYBPC3 was described in the South Asian population. The MYBPC3 d25bp variant is present in approximately 100 million people, and encompasses a splicing branch point predicted to result in abnormal splicing of exon 33. Thus, there is a critical need to understand the mechanism by which MYBPC3 d25bp may cause cardiomyopathy. Methods: To determine the role of the 25bp deletion in vivo , knock-in humanized mice were created in which intron 32 was replaced with the human intron 32, with or without the MYBPC3 d25bp mutation. Mice were characterized at 3- and 6-months of age by echocardiography, histological, and protein analysis. The presence of aberrant exon splicing was also determined in mice carrying the MYBPC3 d25bp variant through RT-PCR and mini-gene assays. Finally, exon trapping experiments were performed to understand the mechanism behind exon skipping. Results: Under baseline conditions, MYBPC3 d25bp displayed no changes in cardiac function or morphology as measured by echocardiography (FS (%): NTG 35.3%, WT 32.8%, Het 33.7%), heart weight to body weight ratio, or histology. While exon 33 skipping was not detected by RT-PCR, the presence of an alternative splice site within exon 33 was identified in MYBPC3 d25bp mice. However, this did not affect the protein levels of cMyBP-C. Furthermore, mini-gene experiments demonstrated that the MYBPC3 d25bp mutation significantly reduced the percentage of correctly spliced transcripts (86.2% vs. 77.5%). Conclusions: These data demonstrate that the presence of the highly prevalent 25bp deletion is not sufficient to cause disease under baseline conditions. However, it is possible that the increased levels of aberrant splicing may increase the risk for developing HCM.
Hospitalization rates related to coordinated home healthcare services with a community oncology practice.
Authors: John F. Sandbach, John Bachelor, Kimberly Larson, Denize Jordan, Janet Mullins, Gregory Sheff
Journal: Journal of Clinical Oncology (2019)

273 Background: Unplanned hospital admissions or hospital re-admissions in cancer patients after discharge cost in excess of 16 billion dollars. Oncology patients are a very high risk of hospitalization despite the involvement of a home healthcare agency. The 30-day medical oncology re-hospitalization rates are reported to be 21.6%. Unplanned hospitalization rates in selected oncology patients over a 12 month period have been reported to be as high as 58%. Methods: A large home health agency and a community based medical oncology practice created a delivery model referred to as the Advanced Community Care Model (ACCM). We are reporting our initial 14 month experience. The initial pilot involved three of the medical group’s six cancer centers. The ACCM created standing intervention orders regarding hydration, nausea/vomiting, central line management, antiemetic and diarrhea and a continuum of monthly management meetings with the agency and the practice. Navigation services by a designated RN were provided. Enhanced interventions with either telephone communication or home visits took place when deemed appropriate. Results: ACCM impacted 60-day hospitalization rates fell a baseline at 6 months into the program from 43% to 22% by the end of the 18 month pilot. Avoidable hospitalizations and re-hospitalizations related to N/V, pain, SOB and infection were less than 10%. The initial program has involved 310 unique patients. Conclusions: The reduction in the 60 day hospitalization rates and the low hospitalization and re-hospitalization rates related to pain control, infection, SOB and infection were below published national averages. The results were felt to be encouraging and the ACCM will be expanded to involve all 7 cancer centers in the practice.
Single Cell Transcriptome Analysis of GATA2 Deficiency in Hematopoiesis Modeled with Induced Pluripotent Stem Cells
Authors: Francis Guitart, Moonjung Jung, Stefan Cordes, Shiqin Yu, Jizhong Zou, So Gun Hong, Vinh Dang, Diego A Espinoza, Amy Hsu, Steven M. Holland, Danielle M. Townsley, Cynthia E. Dunbar, Thomas Winkler
Journal: Blood (2018)
Tobacco Use and Tobacco-Related Behaviors — 11 Countries, 2008–2017
Authors: Indu B. Ahluwalia, René A. Arrazola, Luhua Zhao, Jing Shi, Anna Dean, Edward Rainey, Krishna Palipudi, Evelyn Twentyman, Brian S. Armour
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Each year, tobacco use is responsible for approximately 8 million deaths worldwide, including 7 million deaths among persons who use tobacco and 1.2 million deaths among nonsmokers exposed to secondhand smoke (SHS) (1). Approximately 80% of the 1.1 billion persons who smoke tobacco worldwide reside in low- and middle-income countries (2,3). The World Health Organization's (WHO's) Framework Convention on Tobacco Control (FCTC) provides the foundation for countries to implement and manage tobacco control through the MPOWER policy package,* which includes monitoring tobacco use, protecting persons from SHS, warning them about the danger of tobacco, and enforcing bans on tobacco advertising, promotion, or sponsorship (tobacco advertising) (4). CDC analyzed data from 11 countries that completed two or more rounds of the Global Adult Tobacco Survey (GATS) during 2008-2017. Tobacco use and tobacco-related behaviors that were assessed included current tobacco use, SHS exposure, thinking about quitting because of warning labels, and exposure to tobacco advertising. Across the assessed countries, the estimated percentage change in tobacco use from the first round to the most recent round ranged from -21.5% in Russia to 1.1% in Turkey. Estimated percentage change in SHS exposure ranged from -71.5% in Turkey to 72.9% in Thailand. Estimated percentage change in thinking about quitting because of warning labels ranged from 77.4% in India to -33.0% in Turkey. Estimated percentage change in exposure to tobacco advertising ranged from -66.1% in Russia to 44.2% in Thailand. Continued implementation and enforcement of proven tobacco control interventions and strategies at the country level, as outlined in MPOWER, can help reduce tobacco-related morbidity and mortality worldwide (3,5,6).
Polyphenols Modulate Quiescence/Mobilization of Hematopoietic Immature Cells through APC/EPCR/PAR-1 Axis
Authors: Cristiane O Torello, Erich Vinicius De Paula, Rodrigo Naoto Shiraishi, Tamara C. Lopes de Castro, Fernanda Martins, Fernanda I Della Via, Marisa Claudia Alvarez De Prax, Mary L. S. Queiroz, Sara T. Olalla Saad
Journal: Blood (2018)
A Fully Human Anti-BMP6 Antibody Reduces the Need for Erythropoietin Stimulating Agent in Two Rodent Anemia of Chronic Disease Models
Authors: Verena Petzer, Piotr Tymoszuk, Matthew Wake, Luke Bayliss, Jonathan Papworth, Joana Carvalho, Cecilia Deantonio, Malte Ferdinand Asshoff, Markus Seifert, Sylvia Berger, Dominik Wolf, Günter Weiss, Volker Germaschewski, Igor Theurl
Journal: Blood (2018)
Abstract 401: Polyploidy Increases in Murine Cardiomyocytes Following Myocardial Infarction
Authors: Kathleen M Broughton, David Ebeid, Carolina Esquer, Bingyan Wang, Maryam Moshref, Mark Sussman
Journal: Circulation Research (2019)

Introduction: De novo cardiomyogenesis versus polyploidy in myocardial homeostasis, aging, and response to injury is a controversial research area of intense investigation. Our lab recently created the Fluorescent Ubiquitin Cell Cycle Indicator transgenic (FUCCI-Tg) mouse model to study cardiomyocyte (CM) cell cycle progression. Therefore, the FUCCI-Tg model was used to track CM cell cycle correlated to ploidy state in response to myocardial infarction (MI). Hypothesis: Adult FUCCI-Tg cardiomyocytes progress into S/G2/M phase of cell cycle by 10 days after infarction resulting in binucleation rather than de novo cardiomyogenesis. Methods and Results: CMs isolated from FUCCI-Tg were analyzed 3 and 10 days following MI using confocal microscopy and flow cytometry. At 3 days post-MI, the ratio of mono- to binucleated CMs remained unchanged from non-injury CMs. At day 10 post-MI, frequency of mononuclear CMs significantly decreased compared to normal or 3-day post-MI CMs. Coincident with nucleation state, myocytes were only found to enter S/G2/M phase at day 10 post-MI. These results were verified by visualization of FUCCI in isolated CMs using Amnis ImageStream flow cytometry. Ploidy state and CM size was assessed in the infarction / border (left ventricle (LV)) and remote zone (right ventricle (RV)) at day 10 post-MI and compared to the normal and sham LV and RV. Binucleation significantly increased in the LV after MI compared to normal LV, whereas RV CM binucleation and size significantly increased in both sham and MI at 10 days after MI compared to normal RV. Conclusion: Adult murine CMs enter cell cycle in response to MI but primarily undergo endomitosis / endoreplication rather than complete cell cycle reflecting increases in nucleation and/or myocyte size rather than de novo cardiomyogenesis. Future studies will assess CM ploidy in mouse strains purported to possess enhanced cardiomyogenesis following MI injury and the biological significance of ploidy for mediating myocardial repair.